Tuesday, February 21, 2006 :: SIX CT LASER MAMMOGRAPHY STUDIES TO BE INCLUDED
SIX CT LASER MAMMOGRAPHY STUDIES TO BE INCLUDED
IN EUROPEAN CONGRESS OF RADIOLOGY
SCIENTIFIC SESSIONS

Optical and Molecular Imaging Topics Strongly Represented


Fort Lauderdale, Florida, February 21, 2006—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) will exhibit at the European Congress of Radiology (ECR), in Vienna, Austria, March 3-7, in Expo C, #302. Clinical results from six studies relating to the CT Laser Mammography (CTLM®) system will be presented, providing many insights into applications for cancer detection, cancer staging, and following the course of cancer treatments.

The presentations reflect worldwide clinical and academic interest in a multidisciplinary approach that could improve the accuracy of conventional imaging methods. Molecular imaging approaches such as MRI and Nuclear Medicine are more frequently being used for breast imaging; these presentations demonstrate the clinical recognition that CTLM is gaining.

Presentations include:

Medical University of Vienna/Austria

The value of CT-laser-mammography (CTLM) as an adjunct to mammography and ultrasound in the diagnosis of breast cancer
Daniel Flöry, MD, Thomas Helbich, MD, et al.


Gazi University Hospital, Ankara, Turkey

Role of computer tomography laser mammography (CTLM) in the evaluation of breast lesions
Ayşegül Őzdemir, MD, et al.


University of Muenster Hospital, Muenster, Germany

New developments in molecular imaging and breast cancer
Chris Bremer, MD


Catholic University, Rome, Italy

Primer of breast optical imaging with computed tomography laser mammography (CTLM)
Simona Gaudino, MD, et al.

Computed tomography laser mammography (CTLM) imaging in evaluation response to neoadjuvant chemotherapy in breast cancer patient: Correlation with mammogram, ultrasound, and magnetic resonance imaging
Simona Gaudino, MD, et al.


Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland

Pictures of anatomical vessel structures can simulate malignant angiogenesis in CT-laser mammography
Katarzyna Steinhof, MD, et al.


The studies address the use of CTLM in multidisciplinary breast cancer case assessments and methods to aid interpretation. In addition, the ability of CTLM to follow response to neoadjuvant chemotherapy in breast cancer patients was investigated.

“We are very pleased to have so many presentations on the CTLM system at ECR 2006. The presentation of clinical research from leading medical centers and researchers reinforces CTLM’s role in managing breast cancer,” stated Deborah O’Brien, Senior Vice President of Imaging Diagnostic Systems. “With the increasing interest in optical imaging and the number of publications and presented results, recognition of our laser breast imaging technology’s current and future applications is clearly growing.”

ECR is one of Europe’s best-known radiological Congresses, attracting nearly 15,000 attendees from 90 countries. The Congress features scientific sessions and presentations as well as the technical exhibition.

The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Monday, January 23, 2006 :: CT LASER MAMMOGRAPHY CLINICAL RESULTS TO BE PRESENTED AT MAJOR MIDDLE EAST HEALTH CONFERENCE
CT LASER MAMMOGRAPHY CLINICAL RESULTS TO BE PRESENTED AT MAJOR MIDDLE EAST HEALTH CONFERENCE


Fort Lauderdale, Florida, January 23, 2006—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) will exhibit an array of CT laser breast imaging clinical results at Arab Health 2006, January 22-25 in Dubai, United Arab Emirates. IDSI will be located at stand 2G41.

“Arab Health is an important event for us,” commented Janusz Ostrowski, VP of International Sales at Imaging Diagnostic Systems. “Through our attendance, we are reinforcing the clinical value of CTLM® breast exams to women in the Middle East and supporting our customers in the region. At the upcoming session, we will present clinical CT Laser Mammography cases compared to mammography, ultrasound, and MRI from a number of our luminary sites.”

Featuring concurrent specialist conferences, Arab Health is the largest healthcare exhibition in the Middle East. In 2005, over 28,000 visitors attended.

The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Friday, January 20, 2006 :: IMAGING DIAGNOSTIC SYSTEMS CEO INTERVIEW FEATURED ON WALLSTREETREPORTER.COM
IMAGING DIAGNOSTIC SYSTEMS CEO INTERVIEW FEATURED ON WALLSTREETREPORTER.COM

Transition to Commercial Stage Highlighted

Fort Lauderdale, Florida, January 20, 2006—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) reports that Tim Hansen, CEO of Imaging Diagnostic Systems, was interviewed by the Wall Street Reporter. The audio interview is featured on the Wall Street Reporter website, www.wallstreetreporter.com.

The interview focused on significant progress in transitioning from a development stage to a commercial stage company. PMA status and competitive positioning were also addressed.

To listen to the interview, visit the Wall Street Reporter website, www.wallstreetreporter.com, and go to the “Today’s Interviews” section on the right side of the page. Select the Imaging Diagnostic Systems link under the OTCBB heading.

Wall Street Reporter is the publisher of Wall Street Reporter Magazine, WallStreetReporter.com, and several business journals.

The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com

Tuesday, January 3, 2006 :: IMAGING DIAGNOSTIC SYSTEMS SELECTS M SQUARED ASSOCIATES TO MONITOR CLINICAL TRIALS
IMAGING DIAGNOSTIC SYSTEMS SELECTS M SQUARED ASSOCIATES TO MONITOR CLINICAL TRIALS

Fort Lauderdale, Florida, January 3rd 2006—Imaging Diagnostic Systems, Inc., (OTCBB:IMDS) announced today that M Squared Associates of Washington, DC, has been selected by IDSI to audit and monitor the company’s clinical trials.

“We are very pleased to have M Squared as our clinical trial monitor,” stated Deborah O’Brien, Senior Vice President, IDSI. “It is highly important to us that we have exacting standards for following protocol and ensuring that the data is properly collected. With everything that M Squared has to offer, we look forward to working with them. ”

M Squared Associates will provide both expertise in clinical study management as well as experience with the FDA. The company’s senior staff includes past executive managers from both Fortune 500 and early stage medical device companies, as well as past managers from the FDA Center for Devices and Radiological Health.

“We're very proud to be part of the team for the CTLM clinical study,” said Marie Marlow, President and CEO of M Squared Associates. “We consider it a compliment when a company such as Imaging Diagnostic Systems chooses M Squared Associates as its contract research organization (CRO) partner. The CTLM system could benefit thousands of women with a potential diagnosis of breast cancer, so it's important to me both personally and professionally that this clinical study is well-run and supports a quick FDA approval.”

M Squared Associates was founded in 2001 to specifically serve the clinical and regulatory needs of the medical device industry. The company specializes in bringing medical devices to market.

The CTLM system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems’ website at: www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company’s filing with the Securities Exchange Commission.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup@mindspring.com